reports
- Jacob Mekhael
- Lynn Hautekeete
- Mathijs Geerts Danau
- Michiel Declercq
- Thomas Couvreur
Mdxhealth Reports Preliminary Second Quarter 2025 Results, Reaches Pos...
Mdxhealth Reports Preliminary Second Quarter 2025 Results, Reaches Positive Adjusted EBITDA, and Announces Acquisition of Exosome Diagnostics Business from Bio-Techne Mdxhealth Reports Preliminary Second Quarter 2025 Results, Reaches Positive Adjusted EBITDA, and Announces Acquisition of Exosome Diagnostics Business from Bio-Techne Year-over-year Q2 revenues increased by 20% to $26.6 millionAdjusted EBITDA profitability of $1.4 million for Q2 Agreement to acquire ExoDx Business from Bio-Techne for $15 million in cash and stock over 5 years; acquisition expected to accelerate revenue growt...
- Hilde Van Boxstael
- Livio Luyten
- Lynn Hautekeete
- Michiel Declercq
- Thomas Vranken
Mdxhealth Appoints Michael Holder to Board of Directors and Announces...
Mdxhealth Appoints Michael Holder to Board of Directors and Announces Management Change IRVINE, CA, and HERSTAL, BELGIUM – July 3, 2025 () – MDxHealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a leading precision diagnostics company, today announced the appointment of Michael Holder to its Board of Directors as the Chair of the Audit Committee. Mr. Holder will take the seat of Regine Slagmulder, whose term completed in May. Mr. Holder is a highly accomplished executive with over 30 years of diverse experience, including nine board, four CEO, and five CFO roles across public and pr...
- Thomas Vranken
mdxhealth 1Q25 results emphasize tissue-based growth, adj. EBITDA on t...
mdxhealth reported 1Q25 results, showing $ 24.3m rev (+22% y/y), driven primarily by a 41% rise in tissue-based test volumes. Company is clearly prioritizing the opportunity in tissue-based with higher ASP and margins, as tandem Confirm/GPS is well received by urology practices and pathology labs. Gross margins made a resulting 3 ppt jump y/y to 63.8% while opex remained largely in line, leading to adj. EBITDA of $ -1.3m. Mgmt reiterated its FY25 revenue guidance of $ 108-110m and confirmed it i...
- Hilde Van Boxstael
- Lynn Hautekeete
- Michiel Declercq
- Thibault Leneeuw
- Thomas Couvreur
- Thomas Vranken
- Wim Hoste
- Wim Lewi
MDxHealth Reports Q1-2025 Results
MDxHealth Reports Q1-2025 Results Year-over-year Q1 revenues increase by 22% to $24.3 million71% year-over-year improvement in adjusted EBITDA in first quarterConference call with Q&A today at 4:30 PM ET / 22:30 CET IRVINE, CA, and HERSTAL, BELGIUM – May 14, 2025 () – MDxHealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a leading precision diagnostics company, today announced its financial results for the first quarter ended March 31, 2025. Michael K. McGarrity, CEO of mdxhealth, commented: “mdxhealth delivered a strong first quarter, marked by our 16th consecutive quarter of 20% o...
Mdxhealth to Release First Quarter 2025 Financial Results on May 14
Mdxhealth to Release First Quarter 2025 Financial Results on May 14 Company to Host Conference Call with Live Q&A, May 14, 2025, at 4:30pm ET / 22:30 CET IRVINE, California – April 30, 2025 () – MDxHealth SA (NASDAQ: MDXH), a leading precision diagnostics company, today announced it will release its financial results for the first quarter ended March 31, 2025, after market close on Wednesday, May 14, 2025. Title:Mdxhealth Presents First Quarter 2025 Financial Results andCorporate Update Conference Call and WebcastSpeakers:Michael K. McGarrity, Chief Executive OfficerRon Kalfus, Chief Fin...
- Guy Sips
- Hilde Van Boxstael
- Kristof Samoy
- Michiel Declercq
- Thomas Couvreur
- Thomas Vranken
- Wim Hoste
- Wim Lewi
- Thomas Vranken
mdxhealth FIRST LOOK: Solid FY24 results, adj. EBITDA profitability 1H...
In line with previously reported highlights, mdxhealth's FY24 results feature a strong +28% y/y uptake in revenues, with particular uptake in tissue-based test volumes in Q4. Management reiterates its $ 108-110m FY25 revenue guidance and stresses operating leverage as it confirms adjusted EBITDA profitability by 1H25. In line with the ambitious yet realistic FY25 guidance, we reiterate our $ 4.2 TP and Buy rating.
Mdxhealth Announces Fourth Quarter and Full-Year 2024 Financial Result...
Mdxhealth Announces Fourth Quarter and Full-Year 2024 Financial Results Fourth quarter revenue growth of 28% to $24.7 million2024 revenue growth of 28% to $90.0 million68% improvement in adjusted EBITDA in fourth quarterConference call with Q&A today at 4:30 PM EST / 22:30 CET IRVINE, CA, and HERSTAL, BELGIUM – February 26, 2025 () – MDxHealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a leading precision diagnostics company, today announced its financial results for the fourth quarter and year ended December 31, 2024. Michael K. McGarrity, CEO of mdxhealth, commented: “We are plea...
Mdxhealth to Present Fourth Quarter and Full Year 2024 Financial Resul...
Mdxhealth to Present Fourth Quarter and Full Year 2024 Financial Results and Corporate Update on February 26 Company to Host Conference Call with Live Q&A, February 26, 2025, at 4:30pm ET / 22:30 CET IRVINE, CA, and HERSTAL, BELGIUM – February 12, 2025 () – MDxHealth SA (NASDAQ: MDXH), a leading precision diagnostics company, today announced it will release its financial results for the fourth quarter and full year ended December 31, 2024, after market close on Wednesday, February 26, 2025. Title:Mdxhealth Presents Fourth Quarter and Full Year 2024 Financial Results andCorporate Update Con...
- Guy Sips
- Jacob Mekhael
- Michiel Declercq
- Sharad Kumar S.P
- Thomas Vranken
- Thomas Vranken
mdxhealth FIRST LOOK: FY24 highlights unlock path to EBITDA profitabil...
mdxhealth provides insight into key FY24 parameters, with revenues landing at $ 90m (KBCSe: $ 88.5m) and YE cash at $ 46.8m (KBCSe: $ 47.1m. Revenue guidance for FY25 is set at a narrow yet ambitious range of $ 108-110m, implying a 20-22% y/y increase. We believe that mdxhealth is well-positioned for growth in 2025 now that the commercial engine is firing on all cylinders, hence we maintain our $ 4.2 TP and Buy rating.
MDxHealth Reports Preliminary Fourth Quarter and Full Year 2024 Revenu...
MDxHealth Reports Preliminary Fourth Quarter and Full Year 2024 Revenues and Issues 2025 Revenue Guidance MDxHealth Reports Preliminary Fourth Quarter and Full Year 2024 Revenues and Issues 2025 Revenue Guidance IRVINE, CA – January 13, 2025 () – MDxHealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a leading precision diagnostics company, today reported preliminary fourth quarter and full year 2024 revenues and issued 2025 revenue guidance. The Company expects to report fourth quarter and full year 2024 revenues of approximately $24.7 and $90.0 million, respectively, ...
MDxHealth to Participate in Piper Sandler Healthcare Conference
MDxHealth to Participate in Piper Sandler Healthcare Conference MDxHealth to Participate in Piper Sandler Healthcare Conference IRVINE, CA – November 25, 2024 () – MDxHealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a leading precision diagnostics company, today announced that Michael K. McGarrity, Chief Executive Officer, will participate in the Piper Sandler 36th Annual Healthcare Conference, which will take place between Dec 3-5, 2024, in New York City. Piper Sandler 36th Annual Healthcare ConferenceFireside discussion: Wednesday, December 4, 3:00-3:25 pm ETWebcast: A live w...
- Jacob Mekhael
mdxhealth FIRST LOOK: 3Q24 results come with upgraded FY24 guidance
mdxhealth reported 3Q24 revenue growth of 21% y/y, while management upgraded FY24 guidance to $ 87-89m (previously $ 85-87m) reflecting increased confidence in utilisation from healthcare providers. The goal to reach positive adjusted EBITDA by 1H25 remains on track, and now starts to come into view, while management guided for 20% topline growth for FY25. We reiterate our $ 4.2 TP and Buy rating.
- Hilde Van Boxstael
- Jacob Mekhael
- Kristof Samoy
- Lynn Hautekeete
- Sharad Kumar S.P
- Thibault Leneeuw
- Thomas Couvreur
- Wim Hoste
MDxHealth Reports Results for the Third Quarter and Nine-Month Period ...
MDxHealth Reports Results for the Third Quarter and Nine-Month Period Ended September 30, 2024 Tissue-based test volumes increase by 36%, liquid-based test volumes by 24% Company raises 2024 revenue guidance to $87-89 million, representing 25% growth Pro-forma cash of $53.5 million Conference call and webcast today at 4:30pm ET IRVINE, CA – November 6, 2024 () – MDxHealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a leading precision diagnostics company, today announced its financial results for the third quarter and nine-month period ended September 30, 2024. Michael K. McGar...
MDxHealth to Present Third Quarter 2024 Financial Results and Corporat...
MDxHealth to Present Third Quarter 2024 Financial Results and Corporate Update on November 6 MDxHealth to Present Third Quarter 2024 Financial Resultsand Corporate Update on November 6 Company to Host Conference Call with Live Q&A, November 6, 2024, at 4:30pm ET / 22:30 CET IRVINE, CA, and HERSTAL, BELGIUM – October 14, 2024 () – MDxHealth SA (NASDAQ: MDXH), a commercial-stage precision diagnostics company, today announced it will release its financial results for the third quarter ended September 30, 2024, after market close on Wednesday, November 6, 2024. Title:MDxHealth Presents Third ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.